

Sturgess Nick GBAP

From: Elliott Barry GBAP
Sent: 11 March 2005 10:31
To: Allen Sandra GBAP; Campbell Clive CHBS; Jacobsen Matthew GBAP; Marks Louise GBAP; Sturgess Nick GBAP; Travis Kim GBAP; Wilks Martin CHBS
Subject: Meeting: Parkinsons mouse model - How robust and relevance for risk assessment?

Colleagues,



Brief for 14
March 2005

Re Monday's meeting:

Background

We have recently generated data on paraquat at CTL in a mouse (intraperitoneal dosing) model, which is used externally as a model for Parkinsons disease, and shown an effect of paraquat on one of the parameters measured (neuronal cell loss in the substantia nigra of the brain). This now confirms existing data in the literature on this parameter from other laboratories. However, there are other parameters in the model that are not altered by paraquat administration, and the relevance of the neuronal parameter alone is therefore not clear.

The current proposal for following this includes examining:

- Hazard
challenge hard the observation of neuronal cell loss after PQ dosing, including challenging the mouse model
- Risk
consider the relevance of an ip model to risk assessment

I enclose a presentation on the issue to provide a brief. There will be an introduction at the start of the meeting to focus, but if you can review this, it will help.

The main element of the meeting is to **consider ways in which we can challenge hard the neuronal cell loss findings and the mouse model, with the intent of either showing they are not robust, or satisfying ourselves that they are indeed robust and cannot be challenged.**



Brief for Tech
11 Dec 2004.ppt.

The meeting on Monday 14th HG1 CTL is to allow a brainstorm on the ways we can attack the findings in the above context. An outline agenda is below. If we have time, we will move into considering options for the risk assessment aspect, and consider first the issues of the need for data on kinetics across routes and for tissue levels of PQ.

Please come prepared to have free and lateral thinking on what we could do! I look forward to a stimulating meeting.

With thanks in advance for your participation,

Barry

Agenda

0900 - 0930	Summary of the current mouse model for PD and findings (NS)
0930 - 1100	Challenge the model (All) Brainstorm Approaches emerging Experiments possible

issues arising (eg prf, welfare)

1100 - 1200

Risk Assessment (BME/KT)
Gaining data on relevant routes
kinetics
tissue levels

Effect